Home/Filings/4/0000950170-24-111603
4//SEC Filing

Quirk Gerald E 4

Accession 0000950170-24-111603

CIK 0001556263other

Filed

Oct 1, 8:00 PM ET

Accepted

Oct 2, 5:00 PM ET

Size

8.7 KB

Accession

0000950170-24-111603

Insider Transaction Report

Form 4
Period: 2024-09-30
Quirk Gerald E
Chief Legal Officer
Transactions
  • Tax Payment

    Common Stock

    2024-09-30$2.10/sh3,100$6,51046,657 total
  • Exercise/Conversion

    Common Stock

    2024-09-30+10,00049,757 total
  • Exercise/Conversion

    Restricted Stock Units

    2024-09-3010,00020,000 total
    Common Stock (10,000 underlying)
Footnotes (4)
  • [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
  • [F2]Represents shares used to cover tax withholding on a restricted stock unit release.
  • [F3]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
  • [F4]Represents a restricted stock unit award granted on September 12, 2023. These restricted stock units vested as to one third (1/3rd) of the shares underlying the award on September 30, 2024, and are scheduled to vest as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter.

Documents

1 file

Issuer

Syros Pharmaceuticals, Inc.

CIK 0001556263

Entity typeother

Related Parties

1
  • filerCIK 0001479603

Filing Metadata

Form type
4
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 5:00 PM ET
Size
8.7 KB